Clinical Trial

R-2487 in Patients With Sjogren's Syndrome (SS)

Study acronym: R-2487-SS-01
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Sjogren's Syndrome. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Sjogren's Syndrome. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-03-05; most recent amendment 2025-08-27.
Trial Details
NCT Number NCT06297213
Lead Sponsor Rise Therapeutics LLC
Conditions Sjogren's Syndrome, Sjögren, Sjögren Syndrome, Unspecified
Enrollment 36 participants
Start Date 2026-06-01
Primary Completion 2028-08-30 (estimated)
Study Completion 2028-08-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-04